A Healthy-Volunteer Midazolam Interaction Study Found No Meaningful PF-06751979 Effect

An early-phase development paper reported no clinically meaningful midazolam pharmacokinetic change under one tested PF-06751979 regimen.

A specific interaction question

Alongside safety and biomarker studies of the investigational BACE1 inhibitor, the researchers conducted an interaction study using single-dose midazolam after multiple PF-06751979 doses. The reported conclusion concerned the tested 100 mg once-daily regimen in healthy adults.

Keep a null result within its design

The result is evidence about a particular regimen, population, and probe drug. It does not establish that every dose or duration lacks interaction, or that the investigational drug benefits patients with dementia. The broader early-phase program was limited by small samples, short treatment, and healthy volunteers. Pharmacokinetic neutrality also does not prove that simultaneous central nervous system effects are absent. The study is a useful negative metabolic-interaction finding when cited precisely, rather than a universal assurance about benzodiazepine combinations.

Source paper

Original analysis of the supplied journal article, identified as PMC6839502.

Related research

• Lisdexamfetamine Did Not Meaningfully Change Midazolam Exposure in a Healthy-Volunteer Study
• Short-Term Fasting Study Found Enzyme-Specific Changes Rather Than a General Midazolam Effect